The type 2 asthma mediator IL-13 inhibits SARS-CoV-2 infection of bronchial epithelium

20215 citationsPreprintgreen Open Access

Authors

Luke R. Bonser · University of California, San Francisco

Walter L. Eckalbar · University of California, San Francisco

Lauren Rodriguez · University of California, San Francisco

Jiangshan Jane Shen · University of California, San Francisco

Kyung Duk Koh · University of California, San Francisco

Lorna Zlock · University of California, San Francisco

Stephanie A. Christenson

Abstract

IL-13 markedly reduces susceptibility of HBECs to SARS-CoV-2 infection through mechanisms that likely differ from those activated by type I interferons. Our findings may help explain reports of relatively low prevalence of asthma in patients diagnosed with COVID-19 and could lead to new strategies for reducing SARS-CoV-2 infection.

Topics & Keywords

Asthma and respiratory diseases Immune Cell Function and Interaction IL-33, ST2, and ILC Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: bioRxiv (Cold Spring Harbor Laboratory)

DOI: 10.1101/2021.02.25.432762